AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 30316695 — intervention group
Group type: COMPARATOR
Intervention: Both agents
Number of subjects: 48
Study 27471317 — intervention group
Group type: EXPERIMENTAL
Intervention: Artemether-lumefantrine
Number of subjects: 105
Study 27471317 — intervention group
Group type: EXPERIMENTAL
Intervention: Artemether-lumefantrine with trimethoprim-sulfamethoxazole
Number of subjects: 105
Study 27471317 — intervention group
Group type: EXPERIMENTAL
Intervention: Day 3 concentrations of lumefantrine
Number of subjects: 105
Study 23167308 — intervention group
Group type: EXPERIMENTAL
Intervention: MHBA grafted (TG) - buccal plate thickness ≤ 1 mm (TG-a)
Number of subjects: 31
Study 23167308 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG) - buccal plate thickness ≤ 1 mm (CG-a)
Number of subjects: 31
Study 23167308 — intervention group
Group type: EXPERIMENTAL
Intervention: MHBA grafted (TG) - buccal plate thickness > 1 mm (TG-b)
Number of subjects: 31
Study 23167308 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG) - buccal plate thickness > 1 mm (CG-b)
Number of subjects: 31
Study 22100577 — intervention group
Group type: EXPERIMENTAL
Intervention: Cranberry juice
Number of subjects: 255
Study 22100577 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 255
Study 20735795 — intervention group
Group type: EXPERIMENTAL
Intervention: OFD+EDTA+EMD
Number of subjects: 24
Study 20735795 — intervention group
Group type: COMPARATOR
Intervention: OFD+EDTA
Number of subjects: 24
Study 18844761 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (valsartan + hydrochlorothiazide)
Number of subjects: 0
Study 18844761 — intervention group
Group type: COMPARATOR
Intervention: Monotherapy (valsartan alone)
Number of subjects: 0
Study 16036126 — intervention group
Group type: EXPERIMENTAL
Intervention: Polished with 1,000-grit sandpaper
Number of subjects: 36
Study 16036126 — intervention group
Group type: EXPERIMENTAL
Intervention: Polished with 1,200-grit sandpaper
Number of subjects: 36
Study 16036126 — intervention group
Group type: EXPERIMENTAL
Intervention: Polished with 1,500-grit sandpaper
Number of subjects: 36
Study 16036126 — intervention group
Group type: EXPERIMENTAL
Intervention: Polished with 2,000-grit sandpaper
Number of subjects: 36
Study 16036126 — intervention group
Group type: EXPERIMENTAL
Intervention: Polished with 2,500-grit sandpaper
Number of subjects: 36
Study 16036126 — intervention group
Group type: COMPARATOR
Intervention: Control group polished with 2,500-grit or 1,200-grit sandpaper and immersed in distilled water
Number of subjects: 36
Study 16036126 — intervention group
Group type: EXPERIMENTAL
Intervention: Specimens immersed in coffee solution
Number of subjects: 36
Study 11910259 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 150
Study 11910259 — intervention group
Group type: COMPARATOR
Intervention: Fluoxetine
Number of subjects: 150
Study 10341330 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual genomic screening for HCV RNA using a semi-automated genomic amplification assay
Number of subjects: 8417
Study 10341330 — intervention group
Group type: COMPARATOR
Intervention: Control group not explicitly mentioned
Number of subjects: 8417
Study 8942455 — intervention group
Group type: EXPERIMENTAL
Intervention: Social skills training
Number of subjects: 80
Study 8942455 — intervention group
Group type: COMPARATOR
Intervention: Supportive group therapy
Number of subjects: 80
Study 8942455 — intervention group
Group type: EXPERIMENTAL
Intervention: Social skills training with active drug supplementation
Number of subjects: 80
Study 8942455 — intervention group
Group type: EXPERIMENTAL
Intervention: Social skills training with placebo supplementation
Number of subjects: 80
Study 8942455 — intervention group
Group type: COMPARATOR
Intervention: Supportive group therapy with active drug supplementation
Number of subjects: 80
Study 8942455 — intervention group
Group type: COMPARATOR
Intervention: Supportive group therapy with placebo supplementation
Number of subjects: 80
Study 1840324 — intervention group
Group type: EXPERIMENTAL
Intervention: Teicoplanin 15 mg/Kg iv
Number of subjects: 0
Study 1840324 — intervention group
Group type: EXPERIMENTAL
Intervention: Teicoplanin 20 mg/Kg iv
Number of subjects: 0
Study 1840324 — intervention group
Group type: EXPERIMENTAL
Intervention: Teicoplanin 25 mg/Kg iv
Number of subjects: 0
Study 1840324 — intervention group
Group type: EXPERIMENTAL
Intervention: Four exponential equation
Number of subjects: 0
Study 1840324 — intervention group
Group type: EXPERIMENTAL
Intervention: Tri-exponential model
Number of subjects: 0
Study 7078016 — intervention group
Group type: EXPERIMENTAL
Intervention: Coded commercial artificial tear solution 1
Number of subjects: 17
Study 7078016 — intervention group
Group type: EXPERIMENTAL
Intervention: Coded commercial artificial tear solution 2
Number of subjects: 17
Study 7078016 — intervention group
Group type: EXPERIMENTAL
Intervention: Coded commercial artificial tear solution 3
Number of subjects: 17
Study 7078016 — intervention group
Group type: EXPERIMENTAL
Intervention: Coded commercial artificial tear solution 4
Number of subjects: 17
Study 7078016 — intervention group
Group type: EXPERIMENTAL
Intervention: Function tests (Schirmer test, break‐up time, goblet cell count)
Number of subjects: 17
Study 30799018 — intervention group
Group type: EXPERIMENTAL
Intervention: Plant-based hemostatic powder (PBHP) placed intraoperatively
Number of subjects: 116
Study 30799018 — intervention group
Group type: COMPARATOR
Intervention: Control group (no PBHP)
Number of subjects: 116
Study 28657703 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral gel
Number of subjects: 300
Study 28657703 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral rinse
Number of subjects: 300
Study 28657703 — intervention group
Group type: EXPERIMENTAL
Intervention: Mouth spray
Number of subjects: 300
Study 28657703 — intervention group
Group type: COMPARATOR
Intervention: Water
Number of subjects: 300
Study 26534729 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored practice and patient plans; training sessions for practitioners in medication prescribing and behavioural change; regular patient recall system.
Number of subjects: 903
Study 26534729 — intervention group
Group type: COMPARATOR
Intervention: Usual care (Control group)
Number of subjects: 903
Study 23432339 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin administered at 0.1 μg kg(‐1) h(‐1) for 2 hours
Number of subjects: 18
Study 23432339 — intervention group
Group type: EXPERIMENTAL
Intervention: Population pharmacokinetics of melatonin
Number of subjects: 18
Study 21450183 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral extended-release oxybutynin 5 mg
Number of subjects: 50
Study 21450183 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 19725235 — intervention group
Group type: EXPERIMENTAL
Intervention: Biotene toothpaste
Number of subjects: 30
Study 19725235 — intervention group
Group type: COMPARATOR
Intervention: Colgate Active
Number of subjects: 30
Study 18051826 — intervention group
Group type: EXPERIMENTAL
Intervention: Food challenge (DBPCFC) in children with IgE-related food allergy
Number of subjects: 304
Study 18051826 — intervention group
Group type: COMPARATOR
Intervention: Food challenge (DBPCFC) in children without IgE-related food allergy
Number of subjects: 304
Study 15826410 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term counselling in general practice
Number of subjects: 181
Study 15826410 — intervention group
Group type: COMPARATOR
Intervention: Routine GP treatment (Control)
Number of subjects: 181
Study 12031995 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow Rewarming (n = 15, mean rewarming speed: 0.22 degrees +/- 0.07 degrees C/min)
Number of subjects: 30
Study 12031995 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard Rewarming (n = 15, mean rewarming speed: 0.46 degrees +/- 0.09 degrees C/min)
Number of subjects: 30
Study 12031995 — intervention group
Group type: COMPARATOR
Intervention: Control group (nondiabetic patients)
Number of subjects: 30
Study 12031995 — intervention group
Group type: EXPERIMENTAL
Intervention: Rewarming rates
Number of subjects: 30
Study 12031995 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes
Number of subjects: 30
Study 9871862 — intervention group
Group type: EXPERIMENTAL
Intervention: Timolol hemihydrate 0.5% solution once daily
Number of subjects: 43
Study 9871862 — intervention group
Group type: COMPARATOR
Intervention: Timolol maleate gel 0.5% once daily
Number of subjects: 43
Study 8717212 — intervention group
Group type: EXPERIMENTAL
Intervention: rH‐EPO 9,000 IU intravenously daily
Number of subjects: 86
Study 8717212 — intervention group
Group type: EXPERIMENTAL
Intervention: rH‐EPO 10,500 IU subcutaneously every third day for a week
Number of subjects: 86
Study 8717212 — intervention group
Group type: COMPARATOR
Intervention: rH‐EPO (various doses)
Number of subjects: 86
Study 2142293 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipratropium bromide (IB), 250 micrograms inhalation solution
Number of subjects: 11
Study 2142293 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 343728 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulindac (300-400 mg daily)
Number of subjects: 0
Study 30269430 — intervention group
Group type: EXPERIMENTAL
Intervention: ISBB (Interscalene Brachial Plexus Block) with 20 mL of 0.25% bupivacaine
Number of subjects: 62
Study 30269430 — intervention group
Group type: COMPARATOR
Intervention: SCBB (Supraclavicular Brachial Plexus Block) with 20 mL of 0.25% bupivacaine
Number of subjects: 62
Study 27941393 — intervention group
Group type: EXPERIMENTAL
Intervention: rosuvastatin
Number of subjects: 22
Study 27941393 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 22
Study 25969414 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate-release (IR) tablets, 60 mg (treatment A)
Number of subjects: 18
Study 25969414 — intervention group
Group type: COMPARATOR
Intervention: Powder formulation delivered to the distal small bowel (treatment B)
Number of subjects: 18
Study 25969414 — intervention group
Group type: COMPARATOR
Intervention: Powder formulation delivered to the ascending colon (treatment C)
Number of subjects: 18
Study 25969414 — intervention group
Group type: COMPARATOR
Intervention: Aqueous suspension delivered to the ascending colon (treatment D)
Number of subjects: 18
Study 25969414 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate-release (IR) tablets, 30 mg (treatment E)
Number of subjects: 18
Study 25969414 — intervention group
Group type: COMPARATOR
Intervention: Granulate formulation with fumaric acid 50 mg delivered to the ascending colon (treatment F)
Number of subjects: 18
Study 23778782 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole Salba seeds (7g, 15g, 24g)
Number of subjects: 13
Study 23778782 — intervention group
Group type: EXPERIMENTAL
Intervention: Ground Salba seeds (7g, 15g, 24g)
Number of subjects: 13
Study 23778782 — intervention group
Group type: COMPARATOR
Intervention: Control breads (matched for energy and macronutrient profile)
Number of subjects: 13
Study 21846929 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 72
Study 21846929 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenylephrine group
Number of subjects: 72
Study 21846929 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine group
Number of subjects: 72
Study 21846929 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenylephrine and epinephrine spray group
Number of subjects: 72
Study 17882140 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (50 mg)
Number of subjects: 12
Study 17882140 — intervention group
Group type: EXPERIMENTAL
Intervention: Tyrosine (400 mg)
Number of subjects: 12
Study 17882140 — intervention group
Group type: EXPERIMENTAL
Intervention: Green Tea Extract (500 mg)
Number of subjects: 12
Study 17882140 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 17825137 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxybutynin extended release
Number of subjects: 72
Study 17825137 — intervention group
Group type: COMPARATOR
Intervention: Oxybutynin immediate release
Number of subjects: 72
Study 15630270 — intervention group
Group type: EXPERIMENTAL
Intervention: Concord grape juice (CGJ) 5.5 ml/kg body weight/day for 8 weeks
Number of subjects: 40
Study 15630270 — intervention group
Group type: COMPARATOR
Intervention: Calorie-matched placebo drink
Number of subjects: 40
Study 11758294 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic cholecystectomy (LC)
Number of subjects: 100
Study 11758294 — intervention group
Group type: COMPARATOR
Intervention: Minilaparotomy cholecystectomy (MC)
Number of subjects: 100
Study 9203227 — intervention group
Group type: EXPERIMENTAL
Intervention: Cortisol infusion (15 mg hydrocortisone sodium succinate over 120 min)
Number of subjects: 10
Study 9203227 — intervention group
Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 10
Study 7898091 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambulatory 24-hour blood pressure monitoring
Number of subjects: 0
Study 7898091 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-measured blood pressure at home
Number of subjects: 0
Study 7898091 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambulatory monitoring
Number of subjects: 0
Study 7898091 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-measurement
Number of subjects: 0
Study 3295501 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose methotrexate
Number of subjects: 166
Study 3295501 — intervention group
Group type: COMPARATOR
Intervention: Moderate-dose methotrexate
Number of subjects: 166
Study 3295501 — intervention group
Group type: EXPERIMENTAL
Intervention: Both high-dose and moderate-dose methotrexate
Number of subjects: 166
Study 31462406 — intervention group
Group type: EXPERIMENTAL
Intervention: Intubation and ventilation prior to umbilical cord clamping (UCC)
Number of subjects: 20
Study 31462406 — intervention group
Group type: EXPERIMENTAL
Intervention: Intubation and ventilation prior to UCC
Number of subjects: 20
Study 29625852 — intervention group
Group type: EXPERIMENTAL
Intervention: Homeopathic Q‐potencies of opium and E. coca
Number of subjects: 54
Study 29625852 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study 28852828 — intervention group
Group type: COMPARATOR
Intervention: Normoxia (NM; FiO2 0.21)
Number of subjects: 9
Study 28852828 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe normobaric hypoxia (HY; FiO2 0.13)
Number of subjects: 9
Study 26280790 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 IU vitamin D3 fortified mozzarella cheese with pizza
Number of subjects: 96
Study 26280790 — intervention group
Group type: EXPERIMENTAL
Intervention: 28,000 IU vitamin D3 fortified mozzarella cheese with pizza
Number of subjects: 96
Study 26280790 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose group (28,000 IU)
Number of subjects: 96
Study 26280790 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 96
Study 23053173 — intervention group
Group type: EXPERIMENTAL
Intervention: Lateral or posterior LV lead location
Number of subjects: 797
Study 23053173 — intervention group
Group type: COMPARATOR
Intervention: Anterior LV lead location
Number of subjects: 797
Study 23053173 — intervention group
Group type: EXPERIMENTAL
Intervention: Posterior or lateral LV lead location
Number of subjects: 797
Study 20002361 — intervention group
Group type: COMPARATOR
Intervention: Propofol from Baxter Laboratories mixed with NaCl 0.9%
Number of subjects: 22
Study 20002361 — intervention group
Group type: COMPARATOR
Intervention: Propofol from Baxter Laboratories mixed with 2% lidocaine
Number of subjects: 22
Study 20002361 — intervention group
Group type: COMPARATOR
Intervention: Propofol from Laboratorios Gray mixed with NaCl 0.9%
Number of subjects: 22
Study 20002361 — intervention group
Group type: COMPARATOR
Intervention: Propofol from Laboratorios Gray mixed with 2% lidocaine
Number of subjects: 22
Study 20002361 — intervention group
Group type: COMPARATOR
Intervention: Propofol from Baxter Laboratories
Number of subjects: 22
Study 20002361 — intervention group
Group type: COMPARATOR
Intervention: Propofol from Laboratorios Gray
Number of subjects: 22
Study 17896223 — intervention group
Group type: EXPERIMENTAL
Intervention: Mouse with tactile feedback signal
Number of subjects: 0
Study 17896223 — intervention group
Group type: COMPARATOR
Intervention: Regular computer mouse
Number of subjects: 0
Study 16647634 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol and calcium
Number of subjects: 90
Study 16647634 — intervention group
Group type: EXPERIMENTAL
Intervention: Tibolone and calcium
Number of subjects: 90
Study 16647634 — intervention group
Group type: COMPARATOR
Intervention: Calcium only
Number of subjects: 90
Study 12732840 — intervention group
Group type: EXPERIMENTAL
Intervention: Cremophor RH40 (600 mg 3 times daily)
Number of subjects: 12
Study 12732840 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 10748312 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with chronic heart failure
Number of subjects: 60
Study 10748312 — intervention group
Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 60
Study 10748312 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise time
Number of subjects: 60
Study 10748312 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart rate at peak exercise
Number of subjects: 60
Study 10748312 — intervention group
Group type: EXPERIMENTAL
Intervention: Change in heart rate
Number of subjects: 60
Study 10748312 — intervention group
Group type: EXPERIMENTAL
Intervention: Rate pressure product at peak exercise
Number of subjects: 60
Study 10748312 — intervention group
Group type: EXPERIMENTAL
Intervention: Change in systolic blood pressure
Number of subjects: 60
Study 8761899 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol
Number of subjects: 72
Study 8761899 — intervention group
Group type: COMPARATOR
Intervention: Metoprolol
Number of subjects: 72
Study 1431582 — intervention group
Group type: EXPERIMENTAL
Intervention: Oleic acid-rich diet
Number of subjects: 27
Study 1431582 — intervention group
Group type: EXPERIMENTAL
Intervention: Palmitic acid-rich diet
Number of subjects: 27
Study 1431582 — intervention group
Group type: EXPERIMENTAL
Intervention: Elaidic acid-rich diet
Number of subjects: 27
Study 1431582 — intervention group
Group type: COMPARATOR
Intervention: Butter fat diet
Number of subjects: 27
Study 3857359 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 g CTM, given 4 times daily for 5 days (Group A)
Number of subjects: 47
Study 3857359 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 g CTM, given twice daily for 5 days (Group B)
Number of subjects: 47
Study 30157016 — intervention group
Group type: EXPERIMENTAL
Intervention: Engage program (eight clinic‐based sessions supported by online modules)
Number of subjects: 57
Study 30157016 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 57
Study 27255121 — intervention group
Group type: EXPERIMENTAL
Intervention: Strawberry drink consumed 2 h before the meal (BM)
Number of subjects: 14
Study 27255121 — intervention group
Group type: EXPERIMENTAL
Intervention: Strawberry drink consumed with the meal (WM)
Number of subjects: 14
Study 27255121 — intervention group
Group type: EXPERIMENTAL
Intervention: Strawberry drink consumed 2 h after the meal (AM)
Number of subjects: 14
Study 27255121 — intervention group
Group type: COMPARATOR
Intervention: Control drinks at alternative time points
Number of subjects: 14
Study 24953794 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab 500 mg
Number of subjects: 12
Study 24953794 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab 1000 mg
Number of subjects: 12
Study 24953794 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab (both dosing arms)
Number of subjects: 12
Study 22180589 — intervention group
Group type: EXPERIMENTAL
Intervention: SmokeStop Therapy (SST)
Number of subjects: 0
Study 22180589 — intervention group
Group type: COMPARATOR
Intervention: Minimal Intervention Strategy for Lung patients (LMIS)
Number of subjects: 0
Study 19904250 — intervention group
Group type: EXPERIMENTAL
Intervention: Double-dosed pantoprazole (40 mg twice daily for 8 weeks)
Number of subjects: 200
Study 19904250 — intervention group
Group type: COMPARATOR
Intervention: Standard-dosed pantoprazole (40 mg per day for 8 weeks and one blank tablet at night)
Number of subjects: 200
Study 19904250 — intervention group
Group type: EXPERIMENTAL
Intervention: Double-dosed pantoprazole
Number of subjects: 200
Study 18624724 — intervention group
Group type: EXPERIMENTAL
Intervention: NRTI-sparing regimen
Number of subjects: 100
Study 15954953 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol (30 mg boluses every second minute)
Number of subjects: 20
Study 15954953 — intervention group
Group type: COMPARATOR
Intervention: Nitrous oxide (N2O, premedication with 30 mg propofol 5 min before, increased every other minute in 15% increments, max. 75%)
Number of subjects: 20
Study 15023662 — intervention group
Group type: COMPARATOR
Intervention: No egg
Number of subjects: 41
Study 15023662 — intervention group
Group type: EXPERIMENTAL
Intervention: One cooked egg
Number of subjects: 41
Study 15023662 — intervention group
Group type: EXPERIMENTAL
Intervention: (1/2)cooked egg
Number of subjects: 41
Study 15023662 — intervention group
Group type: EXPERIMENTAL
Intervention: One raw egg
Number of subjects: 41
Study 10758799 — intervention group
Group type: EXPERIMENTAL
Intervention: General anaesthesia (group A)
Number of subjects: 41
Study 10758799 — intervention group
Group type: COMPARATOR
Intervention: Combined general and epidural anaesthesia (group B)
Number of subjects: 41
Study 8835706 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram (CIT) 40 to 60 mg daily for 4 weeks
Number of subjects: 69
Study 8835706 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram (CIT) with lithium carbonate (Li) 2 x 400 mg/day from days 29 to 35
Number of subjects: 69
Study 8835706 — intervention group
Group type: COMPARATOR
Intervention: Citalopram (CIT) with placebo (CIT‐Pl)
Number of subjects: 69
Study 8835706 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram (CIT) with lithium (Li) 800 mg/day from days 36 to 42
Number of subjects: 69
Study 1451222 — intervention group
Group type: EXPERIMENTAL
Intervention: isoflurane-nitrous oxide
Number of subjects: 60
Study 1451222 — intervention group
Group type: EXPERIMENTAL
Intervention: propofol-air
Number of subjects: 60
Study 1451222 — intervention group
Group type: EXPERIMENTAL
Intervention: propofol-nitrous oxide
Number of subjects: 60
Study 1451222 — intervention group
Group type: COMPARATOR
Intervention: All groups
Number of subjects: 60
Study 6486112 — intervention group
Group type: EXPERIMENTAL
Intervention: Breakfast containing greater than 30 g fat
Number of subjects: 15